SMITH & NEPHEW PLC
12 July 2024
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
On 11 July 2024, Smith & Nephew plc (the "Company") received notification of the following transactions as detailed below.
| Reason for the notification | |
| Initial notification /Amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | Smith & Nephew plc |
| LEI | 213800ZTMDN8S67S1H61 |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrument
| Smith & Nephew plc SPON ADR American Depositary Shares (ADS)
|
| Identification code | ISIN: US83175M2052 |
| Nature of the transaction | Purchase of American Depository Shares as participants of the Company's Employee Stock Purchase Plan |
| Date of Transaction | 2024-07-5 |
| Place of Transaction | New York Stock Exchange |
| Name | Director / PDMR | Price ($) | Volume | Aggregated information |
| Deepak Nath (Chief Executive Officer)
| Director | 21.06 | 465.54938 | N/A Single Transaction |
| Paul Connolly (President, Global Operations) | PDMR | 21.06 | 465.54938 | N/A Single Transaction |
| Craig Gaffin (President, Global Orthopaedics)
| PDMR | 21.06 | 465.54938 | N/A Single Transaction |
| Mizanu Kebede (Chief Quality & Regulatory Affairs Officer)
| PDMR | 21.06 | 108.48433 | N/A Single Transaction |
| Scott Schaffner (President, Sports Medicine) | PDMR | 21.06 | 261.92498 | N/A Single Transaction |
Helen Barraclough
General Counsel and Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
